Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patientsLetter Published on 2020-08-122022-11-01 Journal: Critical Care [Category] Coronavirus, MERS, [키워드] Adverse adverse events COVID-19 COVID-19 patient event Favipiravir Nafamostat mesylate Treatment [DOI] 10.1186/s13054-020-03227-4 PMC 바로가기 [Article Type] Letter
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case seriesResearch Letter Published on 2020-07-032022-11-01 Journal: Critical Care [Category] COVID-19, [키워드] case sery Combination Critically ill Favipiravir Nafamostat mesylate Patient Treatment [DOI] 10.1186/s13054-020-03078-z PMC 바로가기 [Article Type] Research Letter
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patientsArticle Published on 2020-05-262023-06-14 Journal: Pharmacology & therapeutics [Category] MERS, SARS, [키워드] βCoV, betacoronavirus ACE2, angiotensin-converting enzyme 2 APC, antigen presenting cell ARDS, adult respiratory distress syndrome ATII, human lung type-II alveolar epithelial cells Camostat mesylate cathepsin L CatL, cathepsin L CatS, cathepsin S CC50, the half cytotoxic concentration ChiCTR, Chinese Clinical Trial Registry Chloroquine COVID-19 COVID-19, coronavirus disease CPE, cytopathic effect DEP, dual-envelop pseudotype EC50, the half effective concentration FDA, Food and Drug Administration GFP, green fluorescent protein HIV, Human immunodeficiency virus IC50, the half maximal inhibitory concentration MERS-CoV, Middle East respiratory syndrome-coronavirus MRSA, methicillin-resistant Staphylococcus aureus MW, molecule weight Nafamostat mesylate Protease inhibitor cocktail RBD, receptor-binding domain S1, S2, spike protein subunits SARS-CoV-2 SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2 SARS-S, SARS S protein SI, selectivity index TMPRSS2, Transmembrane serine protease 2 WHO, World Health Organization [DOI] 10.1016/j.pharmthera.2020.107587 PMC 바로가기 [Article Type] Article